"LB-150 / 17 - Neoantigens that fail to elicit measurable T cell responses following peptide immunization can control tumor growth when delivered using a Listeria-based immunotherapy platform".
It will be interesting to see how this compares to the peptide-based personalized neoantigen vaccines.